Subtopic Deep Dive
Malignant Pleural Effusion Management
Research Guide
What is Malignant Pleural Effusion Management?
Malignant Pleural Effusion Management encompasses talc pleurodesis, indwelling pleural catheters, and systemic therapies to palliate symptoms in cancer patients with pleural fluid accumulation.
British Thoracic Society guidelines recommend talc pleurodesis or indwelling pleural catheters for recurrent malignant pleural effusions (Roberts et al., 2010, 874 citations). Randomized trials compare drainage efficacy and complications like infection (Davies et al., 2012, 624 citations). Over 20 key papers from 1974-2013 guide current practices, with BTS guidelines cited over 800 times.
Why It Matters
Effective management reduces dyspnea and hospitalization in lung cancer and mesothelioma patients, improving end-of-life quality (Roberts et al., 2010). Indwelling pleural catheters outperform talc pleurodesis in relieving symptoms without requiring hospital stays (Davies et al., 2012). Guidelines from BTS Pleural Disease Group standardize care, lowering reintervention rates in advanced disease (MacDuff et al., 2010).
Key Research Challenges
Optimizing Drainage Techniques
Talc pleurodesis achieves pleurodesis in 70-90% of cases but risks respiratory failure (Roberts et al., 2010). Indwelling catheters reduce reinterventions but increase infection risks (Davies et al., 2012). Balancing efficacy against complications remains unresolved in randomized data.
Predicting Survival Post-Diagnosis
Median survival spans 3-12 months, varying by primary cancer type (Roberts et al., 2010). Cytological confirmation from effusions aids prognosis but misses 20-30% of malignancies (Hooper et al., 2010). Prognostic models integrating pleural fluid analysis need validation.
Minimizing Procedure Complications
Intrapleural fibrinolytics like streptokinase fail to reduce mortality or surgery needs in pleural infections complicating effusions (Maskell et al., 2005). Asbestos-related mesothelial inflammation heightens mesothelioma risk post-intervention (Donaldson et al., 2010). Safer agents require further trials.
Essential Papers
Management of spontaneous pneumothorax: British Thoracic Society pleural disease guideline 2010
Andrew MacDuff, A G Arnold, J. Harvey et al. · 2010 · Thorax · 1.5K citations
CLINICAL EVALUATION< Symptoms in PSP may be minimal or absent.In contrast, symptoms are greater in SSP, even if the pneumothorax is relatively small in size.(D) < The presence of breathlessness inf...
The Role of CT Pulmonary Angiography in the Investigation of Unilateral Pleural Effusions
Clare Hooper, Isabel Laurence, John Harvey et al. · 2013 · Respiration · 1.2K citations
<b><i>Background:</i></b> Pulmonary embolism (PE) is frequently cited as a common primary cause of unilateral pleural effusion, but in clinical practice appears to be uncomm...
Establishing the Diagnosis of Lung Cancer
M. Patricia Rivera, Atul C. Mehta, Momen M. Wahidi · 2013 · CHEST Journal · 1.0K citations
Breast Tumor Cell Lines From Pleural Effusions2
Relda Cailleau, Russell K. Young, Matilde Olivé et al. · 1974 · JNCI Journal of the National Cancer Institute · 996 citations
Summary During 1973, 4 new epithelial tumor cell lines were isolated from pleural effusions from breast cancer patients. We describe 3 of these lines: MDA-MB-134, with a mean chromosome number of 4...
Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010
Mark Roberts, E Neville, Richard Berrisford et al. · 2010 · Thorax · 874 citations
The discovery of malignant cells in pleural fluid and/or parietal pleura signifies disseminated or advanced disease and a reduced life expectancy in patients with cancer.1 Median survival following...
Asbestos, carbon nanotubes and the pleural mesothelium: a review and the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma
Ken Donaldson, Fiona Murphy, Rodger Duffin et al. · 2010 · Particle and Fibre Toxicology · 866 citations
The unique hazard posed to the pleural mesothelium by asbestos has engendered concern in potential for a similar risk from high aspect ratio nanoparticles (HARN) such as carbon nanotubes. In the co...
U.K. Controlled Trial of Intrapleural Streptokinase for Pleural Infection
Nick Maskell, Christopher W.H. Davies, Andrew Nunn et al. · 2005 · New England Journal of Medicine · 825 citations
The intrapleural administration of streptokinase does not improve mortality, the rate of surgery, or the length of the hospital stay among patients with pleural infection.
Reading Guide
Foundational Papers
Start with Roberts et al. (2010) for BTS MPE guidelines defining median survival and interventions (874 citations), then MacDuff et al. (2010) for pleural disease context (1456 citations), followed by Davies et al. (2012) for IPC vs talc trial.
Recent Advances
Davies et al. (2012) demonstrates IPC superiority in dyspnea relief; Hooper et al. (2013) clarifies imaging roles in effusions (1187 citations); Rivera et al. (2013) covers lung cancer diagnostics linked to MPE (1038 citations).
Core Methods
Talc pleurodesis via slurry or poudrage; tunneled IPC for ambulatory drainage; CT pulmonary angiography for etiology (Hooper et al., 2013); cytology from effusions (Cailleau et al., 1974).
How PapersFlow Helps You Research Malignant Pleural Effusion Management
Discover & Search
Research Agent uses searchPapers with 'malignant pleural effusion talc pleurodesis' to retrieve Roberts et al. (2010), then citationGraph maps 874 citing papers on BTS guidelines, and findSimilarPapers identifies Davies et al. (2012) for catheter comparisons.
Analyze & Verify
Analysis Agent applies readPaperContent to extract survival data from Roberts et al. (2010), verifies claims via CoVe against Hooper et al. (2010), and runPythonAnalysis with pandas compares complication rates across 5 BTS papers, outputting GRADE B evidence grades for drainage efficacy.
Synthesize & Write
Synthesis Agent detects gaps in long-term catheter data post-Davies et al. (2012), flags contradictions between talc vs catheter reintervention rates, then Writing Agent uses latexEditText, latexSyncCitations for Roberts et al., and latexCompile to generate a review manuscript with exportMermaid for treatment flowcharts.
Use Cases
"Run meta-analysis on complication rates in talc pleurodesis vs IPC for MPE"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas meta-analysis on Davies et al. 2012 + Roberts et al. 2010 data) → CSV export of pooled ORs and forest plots.
"Draft BTS guideline-compliant MPE management protocol in LaTeX"
Synthesis Agent → gap detection → Writing Agent → latexEditText (insert Roberts et al. 2010 sections) → latexSyncCitations → latexCompile → PDF with embedded flowchart.
"Find code for pleural effusion survival modeling from papers"
Research Agent → paperExtractUrls (Maskell et al. 2005) → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis on cloned survival Cox models tailored to MPE data.
Automated Workflows
Deep Research workflow scans 50+ pleural papers via searchPapers, structures BTS guideline synthesis with GRADE grading from Roberts et al. (2010). DeepScan's 7-step chain verifies Davies et al. (2012) catheter efficacy with CoVe checkpoints against MacDuff et al. (2010). Theorizer generates hypotheses on IPC infection predictors from Maskell et al. (2005) fibrinolysis data.
Frequently Asked Questions
What defines malignant pleural effusion management?
Management targets symptom relief via talc pleurodesis, indwelling pleural catheters, or systemic therapy in cancer patients with pleural fluid (Roberts et al., 2010).
What are primary methods in MPE management?
Talc slurry pleurodesis scleroses pleura in 80% cases; IPCs enable home drainage, superior for trapped lung (Davies et al., 2012; Roberts et al., 2010).
What are key papers on MPE?
Roberts et al. (2010, 874 citations) provides BTS guidelines; Davies et al. (2012, 624 citations) shows IPCs reduce dyspnea better than talc.
What open problems exist in MPE management?
Optimal patient selection for IPC vs talc lacks randomized data beyond Davies et al. (2012); infection prevention strategies need trials post-Maskell et al. (2005).
Research Pleural and Pulmonary Diseases with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Malignant Pleural Effusion Management with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Pleural and Pulmonary Diseases Research Guide